PortfoliosLab logoPortfoliosLab logo
NAGE vs. ADMA
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

NAGE vs. ADMA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Niagen Bioscience, Inc (NAGE) and ADMA Biologics, Inc. (ADMA). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, NAGE achieves a -45.91% return, which is significantly higher than ADMA's -57.46% return. Over the past 10 years, NAGE has underperformed ADMA with an annualized return of -5.02%, while ADMA has yielded a comparatively higher 0.37% annualized return.


NAGE

1D
-2.82%
1M
-30.22%
YTD
-45.91%
6M
-47.32%
1Y
-70.80%
3Y*
31.29%
5Y*
-17.39%
10Y*
-5.02%

ADMA

1D
2.11%
1M
-24.73%
YTD
-57.46%
6M
-60.65%
1Y
-62.07%
3Y*
24.20%
5Y*
34.85%
10Y*
0.37%
*Multi-year figures are annualized to reflect compound growth (CAGR)

NAGE vs. ADMA - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
NAGE
Niagen Bioscience, Inc
-45.91%19.89%270.98%-14.88%-55.08%-22.08%11.37%25.66%-41.67%77.64%
ADMA
ADMA Biologics, Inc.
-57.46%6.36%279.42%16.49%175.18%-27.69%-51.25%67.36%-25.55%-37.30%

Correlation

The correlation between NAGE and ADMA is 0.28, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.28

Correlation (3Y)
Calculated over the trailing 3-year period

0.21

Correlation (5Y)
Calculated over the trailing 5-year period

0.29

Correlation (10Y)
Calculated over the trailing 10-year period

0.22

Correlation (All Time)
Calculated using the full available price history since Oct 18, 2013

0.18

The correlation between NAGE and ADMA shifts across timeframes, from 0.18 (all time) to 0.29 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

NAGE:

$290.91M

ADMA:

$1.86B

EPS

NAGE:

$0.22

ADMA:

$0.68

PE Ratio

NAGE:

15.78

ADMA:

11.46

PS Ratio

NAGE:

2.25

ADMA:

3.72

PB Ratio

NAGE:

3.53

ADMA:

4.77

Total Revenue (TTM)

NAGE:

$130.42M

ADMA:

$509.86M

Gross Profit (TTM)

NAGE:

$83.83M

ADMA:

$312.42M

EBITDA (TTM)

NAGE:

$13.37M

ADMA:

$218.74M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

NAGE vs. ADMA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NAGE
NAGE Risk / Return Rank: 33
Overall Rank
NAGE Sharpe Ratio Rank: 11
Sharpe Ratio Rank
NAGE Sortino Ratio Rank: 11
Sortino Ratio Rank
NAGE Omega Ratio Rank: 22
Omega Ratio Rank
NAGE Calmar Ratio Rank: 55
Calmar Ratio Rank
NAGE Martin Ratio Rank: 99
Martin Ratio Rank

ADMA
ADMA Risk / Return Rank: 33
Overall Rank
ADMA Sharpe Ratio Rank: 33
Sharpe Ratio Rank
ADMA Sortino Ratio Rank: 33
Sortino Ratio Rank
ADMA Omega Ratio Rank: 33
Omega Ratio Rank
ADMA Calmar Ratio Rank: 33
Calmar Ratio Rank
ADMA Martin Ratio Rank: 11
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NAGE vs. ADMA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Niagen Bioscience, Inc (NAGE) and ADMA Biologics, Inc. (ADMA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


NAGEADMADifference

Sharpe ratio

Return per unit of total volatility

-1.36

-1.14

-0.22

Sortino ratio

Return per unit of downside risk

-2.54

-1.82

-0.72

Omega ratio

Gain probability vs. loss probability

0.70

0.76

-0.06

Calmar ratio

Return relative to maximum drawdown

-0.93

-0.95

+0.02

Martin ratio

Return relative to average drawdown

-1.36

-1.89

+0.53

NAGE vs. ADMA - Sharpe Ratio Comparison

The current NAGE Sharpe Ratio is -1.36, which is comparable to the ADMA Sharpe Ratio of -1.14. The chart below compares the historical Sharpe Ratios of NAGE and ADMA, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


NAGEADMADifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-1.36

-1.14

-0.22

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.23

0.59

-0.82

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.06

0.01

-0.07

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.03

-0.01

-0.02

Drawdowns

NAGE vs. ADMA - Drawdown Comparison

The maximum NAGE drawdown since its inception was -97.00%, which is greater than ADMA's maximum drawdown of -91.28%. Use the drawdown chart below to compare losses from any high point for NAGE and ADMA.


Loading charts...

Drawdown Indicators


NAGEADMADifference

Max Drawdown

Largest peak-to-trough decline

-97.00%

-91.28%

-5.72%

Max Drawdown (1Y)

Largest decline over 1 year

-76.13%

-65.25%

-10.88%

Max Drawdown (3Y)

Largest decline over 3 years

-76.13%

-68.99%

-7.14%

Max Drawdown (5Y)

Largest decline over 5 years

-88.71%

-68.99%

-19.72%

Max Drawdown (10Y)

Largest decline over 10 years

-93.65%

-86.11%

-7.54%

Current Drawdown

Current decline from peak

-81.64%

-68.34%

-13.30%

Average Drawdown

Average peak-to-trough decline

-75.72%

-53.03%

-22.69%

Ulcer Index

Depth and duration of drawdowns from previous peaks

52.25%

32.90%

+19.35%

Volatility

NAGE vs. ADMA - Volatility Comparison

Niagen Bioscience, Inc (NAGE) and ADMA Biologics, Inc. (ADMA) have volatilities of 20.67% and 20.34%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


NAGEADMADifference

Volatility (1M)

Calculated over the trailing 1-month period

20.67%

20.34%

+0.33%

Volatility (6M)

Calculated over the trailing 6-month period

34.51%

45.37%

-10.86%

Volatility (1Y)

Calculated over the trailing 1-year period

52.25%

54.66%

-2.41%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

77.24%

59.46%

+17.78%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

80.01%

69.03%

+10.98%

Dividends

NAGE vs. ADMA - Dividend Comparison

Neither NAGE nor ADMA has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

NAGE vs. ADMA - Financials Comparison

This section allows you to compare key financial metrics between Niagen Bioscience, Inc and ADMA Biologics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


20.00M40.00M60.00M80.00M100.00M120.00M140.00M20222023202420252026
31.47M
114.49M
(NAGE) Total Revenue
(ADMA) Total Revenue
Values in USD except per share items

NAGE vs. ADMA - Profitability Comparison

The chart below illustrates the profitability comparison between Niagen Bioscience, Inc and ADMA Biologics, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-20.0%0.0%20.0%40.0%60.0%80.0%20222023202420252026
63.5%
70.5%
Portfolio components
NAGE - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Niagen Bioscience, Inc reported a gross profit of 19.98M and revenue of 31.47M. Therefore, the gross margin over that period was 63.5%.

ADMA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported a gross profit of 80.75M and revenue of 114.49M. Therefore, the gross margin over that period was 70.5%.

NAGE - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Niagen Bioscience, Inc reported an operating income of 1.58M and revenue of 31.47M, resulting in an operating margin of 5.0%.

ADMA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported an operating income of 58.27M and revenue of 114.49M, resulting in an operating margin of 50.9%.

NAGE - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Niagen Bioscience, Inc reported a net income of 6.32M and revenue of 31.47M, resulting in a net margin of 20.1%.

ADMA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, ADMA Biologics, Inc. reported a net income of 45.33M and revenue of 114.49M, resulting in a net margin of 39.6%.


Frequently Asked Questions


NAGE and ADMA have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

NAGE has higher volatility (20.67%) compared to ADMA (20.34%). In terms of maximum drawdown, NAGE dropped -97.00% vs ADMA's -91.28%.

ADMA currently has the higher Sharpe Ratio (-1.14 vs -1.36), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for NAGE and ADMA

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer